<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medical Companies &#187; Canada</title>
	<atom:link href="http://www.medicalmagazine.net/medical/canada/feed" rel="self" type="application/rss+xml" />
	<link>http://www.medicalmagazine.net</link>
	<description></description>
	<lastBuildDate>Sun, 25 Jul 2010 22:45:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Angiotech Pharmaceuticals , Inc.</title>
		<link>http://www.medicalmagazine.net/angiotech-pharmaceuticals-inc.html</link>
		<comments>http://www.medicalmagazine.net/angiotech-pharmaceuticals-inc.html#comments</comments>
		<pubDate>Sun, 25 Jul 2010 22:42:21 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Drug Manufacturing]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://www.medicalmagazine.net/?p=2261</guid>
		<description><![CDATA[Angiotech Pharmaceuticals , Inc. 1618 Station Street Vancouver, British Columbia V6A 1B6 Canada Tel: (604) 221-7676 Fax: (604) 221-6915 Industry: Drug Manufacturing, Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for [...]]]></description>
			<content:encoded><![CDATA[<p>Angiotech Pharmaceuticals , Inc.<br />
1618 Station Street<br />
Vancouver, British Columbia V6A 1B6<br />
Canada</p>
<p>Tel: (604) 221-7676<br />
Fax: (604) 221-6915<span id="more-2261"></span></p>
<p>Industry: Drug Manufacturing, Pharmaceuticals<br />
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. ( www.angiotech.com ) </p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/angiotech-pharmaceuticals-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boehringer Ingelheim Corporation</title>
		<link>http://www.medicalmagazine.net/boehringer-ingelheim-corporation.html</link>
		<comments>http://www.medicalmagazine.net/boehringer-ingelheim-corporation.html#comments</comments>
		<pubDate>Sun, 25 Jul 2010 22:39:44 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Drug Manufacturing]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://www.medicalmagazine.net/?p=2253</guid>
		<description><![CDATA[Boehringer Ingelheim Corporation 5180 South Service Road Burlington, Ontario L7L 5H4 Canada Tel: (905) 639-0333 Fax: (905) 681-0194 Industry: Drug Manufacturing, Pharmaceuticals The Boehringer Ingelheim group is one of the world&#8217;s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was [...]]]></description>
			<content:encoded><![CDATA[<p>Boehringer Ingelheim Corporation<br />
5180 South Service Road<br />
Burlington, Ontario L7L 5H4<br />
Canada</p>
<p>Tel: (905) 639-0333<br />
Fax: (905) 681-0194<span id="more-2253"></span></p>
<p>Industry: Drug Manufacturing, Pharmaceuticals<br />
The Boehringer Ingelheim group is one of the world&#8217;s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development. ( www.boehringer-ingelheim.com ) </p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/boehringer-ingelheim-corporation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chronogen Inc.</title>
		<link>http://www.medicalmagazine.net/chronogen-inc.html</link>
		<comments>http://www.medicalmagazine.net/chronogen-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:47:28 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2547</guid>
		<description><![CDATA[Industry: Pharmaceuticals, Biotechnology Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Pharmaceuticals, Biotechnology<br />
Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. ( www.chronogen.com )</p>
<p>Chronogen Inc.<br />
2901 Rachel E. Suite 22<br />
Montreal, Quebec H1W 4A4<br />
Canada</p>
<p>Tel: (514) 521-9595<br />
Fax: (514) 521-1579</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/chronogen-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aventis-Pasteur , Inc.</title>
		<link>http://www.medicalmagazine.net/aventis-pasteur-inc.html</link>
		<comments>http://www.medicalmagazine.net/aventis-pasteur-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:31:49 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2527</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Aventis Pasteur, the vaccines business of Aventis, in 2002, produced 1.4 billion doses of vaccine, making it possible to protect 500 million people across the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. ( [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Aventis Pasteur, the vaccines business of Aventis, in 2002, produced 1.4 billion doses of vaccine, making it possible to protect 500 million people across the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. ( www.aventispasteur.com )</p>
<p>Aventis-Pasteur , Inc.<br />
1755 Steeles Avenue West<br />
Toronto, Ontario M2R 3T4<br />
Canada</p>
<p>Tel: (416) 667-2955<br />
Fax: (416) 667-2900</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/aventis-pasteur-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Network Immunology Inc.</title>
		<link>http://www.medicalmagazine.net/network-immunology-inc.html</link>
		<comments>http://www.medicalmagazine.net/network-immunology-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:30:52 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2523</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Network Immunology Inc. is a vaccine company. The company&#8217;s focus is to commercialize a preventive HIV vaccine invented in 2005 by Dr. Geoffrey W. Hoffmann, the Chief Scientist of the company. The Network Immunology vaccine is for HIV negative persons. The technology is based on a theory of AIDS pathogenesis [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Network Immunology Inc. is a vaccine company. The company&#8217;s focus is to commercialize a preventive HIV vaccine invented in 2005 by Dr. Geoffrey W. Hoffmann, the Chief Scientist of the company. The Network Immunology vaccine is for HIV negative persons. The technology is based on a theory of AIDS pathogenesis developed by Dr. Hoffmann (G. W. Hoffmann (1994) Co-selection in immune network theory and in AIDS pathogenesis, Immunology and Cell Biology, 72, 338-346). A key postulate of the theory was validated in a paper published eight years later (D. C. Douek et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature, 417, 95-98). The global demand for an HIV/AIDS vaccine ia ( www.networkimmunologyinc.com )</p>
<p>Network Immunology Inc.<br />
200 &#8211; 2386 East Mall #6<br />
Vancouver, British Columbia V6T 1Z3<br />
Canada</p>
<p>Tel: (604) 222-3605</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/network-immunology-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>LymphoSign Inc.</title>
		<link>http://www.medicalmagazine.net/lymphosign-inc.html</link>
		<comments>http://www.medicalmagazine.net/lymphosign-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 03:04:44 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2485</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology LymphoSign is developing a number of novel compounds discovered in the laboratory of Dr. Chaim Roifman, the company&#8217;s founder, at The Hospital for Sick Children, Toronto. These compounds inhibit abnormal cellular signalling specific to the growth of cancer cells. LymphoSign&#8217;s lead drug candidate LS104 is nearing completion of pre-clinical testing [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
LymphoSign is developing a number of novel compounds discovered in the laboratory of Dr. Chaim Roifman, the company&#8217;s founder, at The Hospital for Sick Children, Toronto. These compounds inhibit abnormal cellular signalling specific to the growth of cancer cells. LymphoSign&#8217;s lead drug candidate LS104 is nearing completion of pre-clinical testing and has shown great promise as a potential treatment of acute leukemias (ALL and AML) as well as other cancers. LS104 has demonstrated very low or no toxicity toward normal cells. The Cancer Therapeutic Landscape is Changing: The worldwide market for cancer therapeutics is approaching US$15 billion in annual sales. Ten years ago, generic cancer drugs were a substantial portion of a much smaller ( www.lymphosign.com )</p>
<p>LymphoSign Inc.<br />
675 Cochrane Drive 6Th Floor<br />
East Tower Markham, Ontario L3R 0B8<br />
Canada</p>
<p>Tel: (905) 530-2333</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/lymphosign-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amorfix Life Sciences Ltd.</title>
		<link>http://www.medicalmagazine.net/amorfix-life-sciences-ltd.html</link>
		<comments>http://www.medicalmagazine.net/amorfix-life-sciences-ltd.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:29:16 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2433</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMP) are prevalent. These include Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer&#8217;s [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMP) are prevalent. These include Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer&#8217;s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson&#8217;s Disease (PD). The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on AMP ( www.amorfix.com )</p>
<p>Amorfix Life Sciences Ltd.<br />
3080 Yonge St. Suite 6020<br />
Toronto, Ontario M4N 3N1<br />
Canada</p>
<p>Tel: (416) 482-3814<br />
Fax: (416) 482-3811</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/amorfix-life-sciences-ltd.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ImmunoVaccine Technologies Inc.</title>
		<link>http://www.medicalmagazine.net/immunovaccine-technologies-inc.html</link>
		<comments>http://www.medicalmagazine.net/immunovaccine-technologies-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:17:56 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2415</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology ImmunoVaccine Technologies Inc. (IVT) is a biotechnology research company based in Halifax, Nova Scotia, Canada. We are currently commercializing novel innovative vaccine technology featuring a unique liposome-based formulation that provides an enhanced immune response following a single administration. We currently have an opportunity for a Microbiology/Immunology Technician. The successful candidate [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
ImmunoVaccine Technologies Inc. (IVT) is a biotechnology research company based in Halifax, Nova Scotia, Canada. We are currently commercializing novel innovative vaccine technology featuring a unique liposome-based formulation that provides an enhanced immune response following a single administration. We currently have an opportunity for a Microbiology/Immunology Technician. The successful candidate will have a M. Sc. in one or more of the following disciplines: microbiology, immunology, cell biology, molecular biology, or biochemistry with relevant lab experience (minimum 1 ( www.immunovaccine.com )</p>
<p>ImmunoVaccine Technologies Inc.<br />
1819 Granville Street Suite 303<br />
Halifax, Nova Scotia B3J 3R1<br />
Canada</p>
<p>Tel: (902) 492-1819<br />
Fax: (902) 492-0888</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/immunovaccine-technologies-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ellipsis Biotherapeutics Corporation</title>
		<link>http://www.medicalmagazine.net/ellipsis-biotherapeutics-corporation.html</link>
		<comments>http://www.medicalmagazine.net/ellipsis-biotherapeutics-corporation.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:01:55 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2381</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology About Ellipsis: Ellipsis is a privately held drug discovery company with lead candidates in the diagnosis and treatment of Degenerative Neurologic Disorders, specifically Alzheimer&#8217;s Disease. In addition, the company has discovery programs in Inflammatory Diseases, including Inflammatory Bowel Disease and Rheumatoid Arthritis. Ellipsis&#8217; central business strategy is to develop therapeutics [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
About Ellipsis: Ellipsis is a privately held drug discovery company with lead candidates in the diagnosis and treatment of Degenerative Neurologic Disorders, specifically Alzheimer&#8217;s Disease. In addition, the company has discovery programs in Inflammatory Diseases, including Inflammatory Bowel Disease and Rheumatoid Arthritis. Ellipsis&#8217; central business strategy is to develop therapeutics and diagnostics through early clinical proof (Phase I/II of clinical trials) and partner downstream commercialization and marketing. With future projects, Ellipsis intends to retain the rights to identified compounds through later stages of the discovery and clinical trials process before seeking commercialization ( www.ellipsis.com )</p>
<p>Ellipsis Biotherapeutics Corporation<br />
700 Bay Street Suite 2101, Box 195<br />
Toronto, Ontario M5G 1Z6<br />
Canada</p>
<p>Tel: (416) 586-0281<br />
Fax: (416) 586-0638</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/ellipsis-biotherapeutics-corporation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Allon Therapeutics Inc.</title>
		<link>http://www.medicalmagazine.net/allon-therapeutics-inc.html</link>
		<comments>http://www.medicalmagazine.net/allon-therapeutics-inc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:01:05 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Canada]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2377</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer&#8217;s disease, mild cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol &#8220;NPC&#8221; (Neuro Protection Company) and based in [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer&#8217;s disease, mild cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol &#8220;NPC&#8221; (Neuro Protection Company) and based in Vancouver. ( www.allontherapeutics.com )</p>
<p>Allon Therapeutics Inc.<br />
506 1168 Hamilton Street<br />
Vancouver, British Columbia V6B 2S2<br />
Canada</p>
<p>Tel: (604) 736-0634<br />
Fax: (604) 736-1616</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/allon-therapeutics-inc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

